For each of the following clinical scenarios requiring targeted biologic therapy, select the precise immunopathologic mechanism of the most appropriate therapeutic agent.
- A 32-year-old woman with highly active relapsing-remitting multiple sclerosis requires escalation of therapy. Serological testing for the John Cunningham (JC) virus is negative.Blockade of alpha-4 integrin, preventing leukocyte transmigration across the blood-brain barrier
- A 45-year-old man with medically refractory chronic spontaneous urticaria continues to experience daily wheals and severe pruritus despite maximum tolerated doses of second-generation H1-antihistamines.Binding of circulating IgE, preventing its attachment to high-affinity Fc-epsilon receptors on mast cells
- A 28-year-old woman is diagnosed with severe fistulizing Crohn disease and concurrent moderate-to-severe plaque psoriasis. She requires induction and maintenance therapy.Inhibition of the shared p40 subunit, neutralizing interleukin-12 and interleukin-23 signaling pathways
- A 55-year-old man with newly diagnosed microscopic polyangiitis and rapidly progressive glomerulonephritis requires non-glucocorticoid induction therapy.Depletion of mature B lymphocytes via binding to the CD20 cell surface antigen
Answer
The correct matches align each specific autoimmune or inflammatory condition with the precise molecular target of its corresponding first-line or escalation biologic agent: MS with alpha-4 integrin blockade, chronic urticaria with IgE binding, Crohn/psoriasis with IL-12/23 p40 inhibition, and microscopic polyangiitis with CD20 depletion.
Each clinical presentation requires a specific immunomodulator whose mechanism precisely targets the underlying pathophysiology of the disease. Natalizumab blocks leukocyte CNS entry in MS. Omalizumab neutralizes IgE in chronic urticaria. Ustekinumab halts the IL-12/23 inflammatory cascade in Crohn disease and psoriasis. Rituximab depletes the autoantibody-producing B cells in ANCA-associated vasculitis.
Step-by-Step Solution
Key Concept
Understanding the precise immunologic targets of monoclonal antibodies is essential for selecting appropriate therapies and anticipating specific adverse effects or contraindications (e.g., PML risk with alpha-4 integrin blockade).